Johnson & Johnson defies market slump with 15% stock surge in 2024

Johnson & Johnson has shown resilience in a shaky market this year. While the S&P 500 has fallen, the healthcare giant's stock has risen by 15%. Investors continue to favour the company for its steady performance and reliable returns.

The firm's strength comes from a broad product range, with 28 platforms or products each generating over $1 billion annually. These span areas like oncology, immunology, neuroscience, surgery, and vision. Even after losing exclusivity for its top-selling drug, Stelara, J&J has moved past the setback, calling it a closed chapter.

Last year, the company split off its consumer health division into Kenvue. This allowed J&J to focus on its core businesses: innovative medicines and medical technology. The shift has not weakened its financial position, as strong free cash flow supports ongoing dividend growth. For income investors, J&J remains a standout choice. It currently pays a dividend of $5.20 per share, yielding 2.1%—nearly double the S&P 500's average. The company also holds the title of Dividend King, having raised its payout annually for over 50 years.

J&J's stock performance and dividend reliability make it a favoured long-term investment. The company's ability to adapt—through strategic spin-offs and a diversified portfolio—helps it weather market downturns. With consistent demand for healthcare products, its position remains solid.